CEL-SCI Corp

CVM

Market cap $69M

Vienna, Virginia--(Newsfile Corp. - October 10, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the LD Micro "Main Event" Investor Conference on October 21, 2025 at 9:30 a.m. PST. The Conference is taking place at the Hotel Del Coronado in San Diega, CA from October 19-21, 2025.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $10 million public offering.

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces pricing of $10 million public offering.

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in a best-efforts public offering. All of the shares of common stock (and/or Pre-Funded Warrants) are being offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal third quarter 2025 financial results.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $5.7 million offering priced at-the-market under NYSE American rules.

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces pricing of $5.7 million offering priced at-the-market under NYSE American rules.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to sign partnership agreement with leading Saudi Arabian pharma company for Multikine in the treatment of head & neck cancer.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HNSCC--FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine.